Ilumetri 100 mg solution for injection in pre-filled syringe
Sponsors
Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Iqvia Biotech Limited, Labcorp Central Laboratory Services SARL
Conditions
Psoriatic Arthritis
Phase 3
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.
Active, not recruitingCTIS2022-501480-41-00
Start: 2023-04-06Target: 247Updated: 2025-12-30
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Active, not recruitingCTIS2023-507415-35-00
Start: 2021-01-15Target: 204Updated: 2025-04-10
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
CompletedCTIS2024-512142-42-00
Start: 2021-10-05End: 2025-04-10Target: 108Updated: 2025-03-17